Evidence map›Paper›PMID 42624887›Full record

ArticleBritish journal of cancer2026

Role of orphan G protein-coupled receptor GPR52 in breast cancer cell multicellular organization and collective invasion.

Sarah Z Hanif, Caleb Kutz, CheukMan Cherie Au, Ingrid Torregroza, Sailesh Palikhe, Syeda Y Jannath, Tabassum Fabiha, Bhavneet Bhinder, Michael P Washburn, Dominic Devost and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Sarah Z HanifWeill Cornell Medicine/Rockefeller University/Memorial Sloan-Kettering Cancer Center Tri-Institutional MD-PhD Program, New York, NY, USA.
Caleb KutzUniversity of Kansas Cancer Center, Kansas City, KS, USA.
CheukMan Cherie AuDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Ingrid TorregrozaDepartment of Surgery, Weill Cornell Medicine, New York, NY, USA.
Sailesh PalikheUniversity of Kansas Cancer Center, Kansas City, KS, USA.
Syeda Y JannathDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Tabassum FabihaColumbia University Computational & Systems Biology Program, Sloan-Kettering Institute of Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Bhavneet BhinderCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Michael P WashburnUniversity of Kansas Cancer Center, Kansas City, KS, USA.
Dominic DevostDepartment of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada.
Shuchen LiuDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Priya BhardwajDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Todd EvansDepartment of Surgery, Weill Cornell Medicine, New York, NY, USA.
Xiaobo LiangDepartment of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, KS, USA.
Pradeep Kumar AnandDivision of Genetic, Environmental and Inhalational Disease, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Robert TarranDivision of Genetic, Environmental and Inhalational Disease, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8061-9617
Lukas E DowDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-7048-1418
John BlenisSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Terence E HébertDepartment of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada.
Kristy A BrownDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA. kbrown46@kumc.edu.ORCID http://orcid.org/0000-0003-3382-5546

Funding

Weill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6M
U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32GM152349V Foundation for Cancer Research (V Foundation) T2025-007
6 · The paper itself

Abstract

backgroundG protein-coupled receptors (GPCRs) are the largest class of membrane-bound receptors and are emerging as targets for the effective treatment of cancer. The role of orphan GPCR GPR52 in cancer has not been characterized. Low mRNA expression of GPR52 in breast tumours correlates with reduced overall survival, leading to the hypothesis that loss of GPR52 supports breast cancer progression.

methodsCRISPR-Cas9 was used to knock out GPR52 in the human triple-negative breast cancer cell lines MDA-MB-468 and MDA-MB-231. 2D and 3D in vitro studies, electron microscopy, and a zebrafish xenograft model were used to assess the morphology and behaviour of GPR52 KO cells.

resultsLoss of GPR52 was associated with elevated levels of cAMP, increased cell-cell interaction in 2D cultures, more spindle-like morphology on collagen, altered 3D spheroid morphology, and increased propensity to organize and invade collectively. Zebrafish injected with GPR52 KO cells developed a greater total cancer area than control. RNA sequencing and proteomic analyses of GPR52-null cells revealed an increased cAMP signalling signature. Re-expression of GPR52 and inhibition of cAMP production rescued some GPR52 KO phenotypes.

conclusionsGPR52 loss is a potential mechanism by which breast cancer progression may occur and supports the investigation of GPR52 agonism as a therapeutic option for breast cancer. STATEMENT OF SIGNIFICANCE: Loss of the orphan GPCR GPR52 in human breast cell lines leads to increased cell clustering, hybrid/partial EMT, and increased tumour burden in zebrafish, further expanding our understanding of mechanisms driving cancer progression and opening the door to novel therapeutic approaches.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.